Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Non-Hodgkin Lymphoma · Advanced Solid Tumors · ADCT

ADC Therapeutics

ADC Therapeutics SA

ADC Therapeutics clinical programs — 30 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Lausanne, Vaud, Switzerland, CH HQ
2011 Founded
272 Employees
Public company Type
ADCT · NYSE Ticker
Company details
Status
Public
HQ
Lausanne, Vaud, Switzerland, CH
Founded
2011
Employees
272
Programs
30
Drugs
15
Patents
22
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

ADC Therapeutics projects

30 ClinicalTrials.gov programs sponsored by ADC Therapeutics.

ADC Therapeutics has 30 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

30 programs

Clinical programs

  1. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  2. Odronextamab

    ADC Therapeutics SA

    B-cell Non Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  3. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  4. ADCT-602

    ADC Therapeutics SA

    Blasts 5 Percent or More of Bone Marrow Nucleated Cells

    phase 2 mab terminated

    1 trial

  5. Camidanlumab Tesirine

    ADC Therapeutics SA

    Relapsed Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  6. Cyclophosphamide

    ADC Therapeutics SA

    Double-Expressor Lymphoma

    phase 2 small molecule active

    1 trial

  7. Epcoritamab

    ADC Therapeutics SA

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  9. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed or Refractory Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. Loncastuximab Tesirine

    ADC Therapeutics SA

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial

  11. Loncastuximab Tesirine

    ADC Therapeutics SA

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    4 trials

  12. Loncastuximab tesirine

    ADC Therapeutics SA

    Post-transplant Lymphoproliferative Disorder

    phase 2 small molecule active

    1 trial

  13. Loncastuximab tesirine

    ADC Therapeutics SA

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  14. Loncastuximab tesirine

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma Refractory

    phase 2 small molecule completed

    1 trial

  15. Loncastuximab tesirine 150 µg/Kg

    ADC Therapeutics SA

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  16. imvotamab

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  17. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  18. ADCT-301

    ADC Therapeutics SA

    Head and Neck Cancer Squamous Cell Carcinoma

    phase 1 small molecule terminated

    1 trial

  19. ADCT-402

    ADC Therapeutics SA

    Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  20. ADCT-402

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  21. ADCT-402-105

    ADC Therapeutics SA

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  22. ADCT-502

    ADC Therapeutics SA

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  23. ADCT-601

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule terminated

    2 trials

  24. ADCT-901

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  25. Camidanlumab tesirine

    ADC Therapeutics SA

    Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  26. Carmustine

    ADC Therapeutics SA

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  27. Loncastuximab Tesirine

    ADC Therapeutics SA

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  28. Loncastuximab Tesirine and Acalabrutinib

    ADC Therapeutics SA

    Chronic Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

  29. Loncastuximab Tesirine and Durvalumab

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  30. Loncastuximab tesirine and rituximab (Lonca-R)

    ADC Therapeutics SA

    Central Nervous System Lymphoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does ADC Therapeutics have?

30 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.